Patients With Hepatitis C Virus Genotype 2 Infection
Conditions
Interventions
None listed
Sponsors
Ogaki Municipal Hospital
Internal Medicine, Japanese Red Cross Society Himeji Hospital Department of Hepatology, Kagawa Prefectural Central Hospital Center for Gastroenterology, Teine Keijinkai Hospital Gastroenterology Center, Ehime Prefectural Central Hospital Division of Gastroenterology and Hepatology, Department of Internal Medicine, Otakanomori Hospital Department of Gastroenterology, Asahi General Hospital Department of Hepatology, Saiseikai Niigata Daini Hospital Department of Gastroenterology, Okayama Ci
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: More than 20 years old and had chronic infection with HCV genotype 2. With or without Child-Pugh A compensated cirrhosis. Body weight more than 40 kg. Written informed consent
Exclusion criteria
Exclusion criteria: Prior exposure to a direct-acting antiviral agent targeting HCV NS5A or NS5B Decompensated cirrhosis Creatinine clearance (Cockcroft-Gault) less than 30 mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and efficacy of ledipasvir-sofosbuvir for 12 weeks treatment with Japanese GT2 patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion rate for treatment completion (without discontinuation of safety reason). | — |
Countries
Japan
Contacts
Public ContactTakashi Kumada
Gifu Kyoritsu University Department of Nursing, Faculty of Nursing
Outcome results
None listed